The company's Q1 results missed estimates but its performance "validates the strength, durability and flexibility of our business model.”
Mercer offers a comprehensive look at what health plan sponsors should be thinking about this contract season.
The long-entrenched system of drug-manufacturer rebates has not adapted to changes in health-plan designs and labor-market trends.
Annual hikes remain historically low for a second consecutive year, partly in response to corporate benefits strategies.
